U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07042100) titled 'A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.' on May 28.
Brief Summary: This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
BIOLOGICAL: Dose level (DL)1
Administered IV every 3 weeks
BIOLOGICAL: DL2
Administered IV every 3 weeks
BIOLOGICAL: DL3
Administered IV every 3 weeks
BIOLOGI...